Navigation Links
UCLA stem cell researchers move toward treatment for rare genetic nerve disease
Date:5/10/2013

Led by Dr. Peiyee Lee and Dr. Richard Gatti, researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have used induced pluripotent stem (iPS) cells to advance disease-in-a-dish modeling of a rare genetic disorder, ataxia telangiectasia (A-T).

Their discovery shows the positive effects of drugs that may lead to effective new treatments for the neurodegenerative disease. iPS cells are made from patients' skin cells, rather than from embryos, and they can become any type of cells, including brain cells, in the laboratory. The study appears online ahead of print in the journal Nature Communications.

People with A-T begin life with neurological deficits that become devastating through progressive loss of function in a part of the brain called the cerebellum, which leads to severe difficulty with movement and coordination. A-T patients also suffer frequent infections due to their weakened immune systems and have an increased risk for cancer. The disease is caused by lost function in a gene, ATM, that normally repairs damaged DNA in the cells and preserves normal function.

Developing a human neural cell model to understand A-T's neurodegenerative process and create a platform for testing new treatments was critical because the disease presents differently in humans and laboratory animals. Scientists commonly use mouse models to study A-T, but mice with the disease do not experience the more debilitating effects that humans do. In mice with A-T, the cerebellum appears normal and they do not exhibit the obvious degeneration seen in the human brain.

Lee and colleagues used iPS cellderived neural cells developed from skin cells of A-T patients with a specific type of genetic mutation to create a disease-in-a-dish model. In the laboratory, researchers were able to model the characteristics of A-T, such as the cell's lack of ATM protein and its inability to repair DNA damage.
'/>"/>

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Researchers Pinpoint Cause of Port-Wine Stain Birthmarks
2. Duke researchers describe how breast cancer cells acquire drug resistance
3. CWRU School of Medicine researchers discover new target for personalized cancer therapy
4. U of M researchers discover link between heart, blood, and skeletal muscle
5. Researchers determine where best to place defibrillators
6. Researchers plot locations where AEDs could save more lives
7. Gene Mutation Linked to Migraines, Researchers Say
8. Discovery of New Cause of Congenital Hydrocephalus Opens the Door to Collaborative Research Study, Hydrocephalus Association Commends Researchers
9. Northwestern Medicine researchers work to improve heart attack response time
10. NYU and NYU Langone researchers devise method for enhancing CEST MRI
11. Medicaid-insured children have limited access to dermatologists, SLU researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... patients die annually as a result of preventable medical harm—this ... each day. Now more than ever before, hospitals and patients ... they can to stay safe. , Through an exclusive ... discusses the importance of safer hospitals. “It’s incumbent upon all ... ensure that all our patients are in the safest environment ...
(Date:2/27/2015)... 27, 2015 Muscular Dystrophy Association ... Engineering at Duke University, recently announced a potentially ... young men with Duchenne muscular dystrophy (DMD). The ... and Gersbach will discuss their implications at MDA's ... in Washington, D.C. , Background: Gersbach and ...
(Date:2/27/2015)... 2015 Over 440,000 patients die each year ... now to educate readers on how they can take control ... serve as a guide to educate and inspire readers to ... loved ones safe with tips on topics ranging from hospital ... cover of the print publication. He recently spoke to ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 With cases of ... Dade area, concerned parents look to school administrations to help ... screenings. Though head lice is a common parasite that passes ... a nuisance, causing parents and teachers significant distress. , ... screenings at the school. This would allow parents and ...
(Date:2/27/2015)... Schenectady, New York (PRWEB) February 27, 2015 ... has been named one of the Best Companies to ... , “Transfinder recognizes the importance of creating a great ... a demanding – yet professionally fulfilling – environment. There’s ... doing great work together,” said Antonio Civitella, president and ...
Breaking Medicine News(10 mins):Health News:Dr. Richard Carmona, the 17th U.S. Surgeon General, and IntelliCentrics Raise Awareness in Mediaplanet’s “Patient Safety” Campaign 2Health News:Statement: New MDA-Funded Genetic Therapy Technique Targets DMD 2Health News:Safe and Sound: Improving Patient Outcomes through Mediaplanet’s “Patient Safety” Campaign 2Health News:South Florida Parents Put Pressure on Schools to Perform Lice Screenings to Prevent Spread of Lice According to One Miami Lice Removal Company Called Lice Troopers 2Health News:Transfinder Named a Best Company to Work for in New York State 2
... PLC (OTC,Bulletin Board: SNKTY), a Life Sciences company ... science of healthy aging, today announced,that its North ... an,amount up to $28 million to further advance ... including Invicorp(R)., Plethora Solutions Holdings PLC, a ...
... the POA, indicator reporting requirements by implementing data elements that expand, ... healthcare ... claims., ... their commitment for continuous improvement is,evident by assisting clients with compliance ...
... for future of loved ones with special ... ... Mutual,Life Insurance Company (MassMutual) today made available on its Web site a,free ... begin,developing or supplementing life care plans for family members with a,disability or ...
... ... With U.S. Presence, AMSTERDAM, The Netherlands, ... evolving field of cancer molecular diagnostics,today announced the appointment of Richard ... medical officer (CMO). Dr. Bender, who,will report directly to Chief Executive ...
... The U.S. Agency,for International Development (USAID) highlights ... the Agency,s community partnerships,in Africa as part of ... this,week. Admiral Timothy Ziemer, U.S. Malaria Coordinator, and ... join Jay Hein,Director of the White House Office ...
... the California NanoSystems Institute at UCLA have developed a novel ... inside tiny pores and release them into cancer cells in ... "nanoimpeller," the device is the first light-powered nanomachine that operates ... for cancer treatment. , UCLA researchers reported ...
Cached Medicine News:Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 2Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 3Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 4Health News:Data Dimensions Assists Clients With Compliance of 'Present on Admission' (POA) Indicator Reporting Requirements as Part of the April 1, 2008 Timeline 2Health News:MassMutual Offers Free 'Letter of Intent' Template to People with Disabilities and Their Families, Caregivers 2Health News:MassMutual Offers Free 'Letter of Intent' Template to People with Disabilities and Their Families, Caregivers 3Health News:Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer 2Health News:Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer 3Health News:USAID Participates in White House Office of Faith-Based and Community Initiatives Conferences in Rwanda and Zambia 2Health News:UCLA researchers design nanomachine that kills cancer cells 2Health News:UCLA researchers design nanomachine that kills cancer cells 3
(Date:2/27/2015)... -- Report Details   Translational ... progress, and predicted revenues ,Where is the market for ... prospects for this market and related technologies? Visiongain,s brand ... to 2025, discussing data, opportunities and prospects. ... medicine : cell-based therapies that aim to restore function ...
(Date:2/27/2015)... Feb. 27, 2015  In recognition of Rare Disease ... the global bleeding disorders community, CSL Behring ... units (IUs) of protein therapies to the World Federation ... organization which has worked to improve the lives of ... donation supports the WFH,s Global Alliance for Progress (GAP) ...
(Date:2/27/2015)...  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the fourth quarter and full year ended December ... year for PTC. We are now a growing commercial-stage ... in the rare disease space," stated Stuart W. Peltz, ... proud to bring the first treatment for Duchenne muscular ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11
... McLaren Health Care and its Great,Lakes Cancer ... medical,minds to share the latest work underway around ... October 11th symposium, hosted by,McLaren and GLCI, was ... oncologist whose work in sentinel node mapping for,colorectal ...
... Changes Induced by ... in Patients with Celiac Disease, Additional Data Indicates Potential in ... Alba Therapeutics Corporation,presented results from two clinical studies this week ... Data from,study CLIN 1001-004, the first Phase IIa trial conducted ...
Cached Medicine Technology:News Media Advisory: World's Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6